Serving the Society Since 1986
Advanced Search
Volume 36 Issue 3
June 2021
    Citation: Mengwei Li, Yuxu Wang, Jing Jin, Jie Dou, Qinglong Guo, Xue Ke, Changlin Zhou, Min Guo. Inhibitory Activity of Honeysuckle Extracts against Influenza A Virus In Vitro and In Vivo .VIROLOGICA SINICA, 2021, 36(3) : 490-500.  http://dx.doi.org/10.1007/s12250-020-00302-6
    shu

    Inhibitory Activity of Honeysuckle Extracts against Influenza A Virus In Vitro and In Vivo

    cstr: 32224.14.s12250-020-00302-6
    • 1.

      State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, China

    • 2.

      Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, Nanjing 210009, China

    • 3.

      Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China

    • Corresponding author: Changlin Zhou, cl_zhou@cpu.edu.cn, ORCID: http://orcid.org/0000-0001-5910-4259
      Min Guo, 1020152471@cpu.edu.cn, ORCID: http://orcid.org/0000-0002-5342-8663
    • Mengwei Li and Yuxu Wang contributed equally to this work.
    • Received Date: 19 July 2019
      Accepted Date: 11 September 2020
      Published Date: 12 October 2020
      Available online: 01 June 2021

    • Honeysuckle has been used in the treatment of influenza virus infection for thousands of years in China. However, its main active components and the functional mechanisms remain to be elucidated. Here, four honeysuckle extracts, including acids extract, flavonoids extract, total extract and acids-flavonoids mixture, were prepared to clarify the main active antiviral components. The cytopathic effect reduction assay showed that all the four extracts inhibited the replication of influenza viruses H1N1, H3N2 and the oseltamivir-resistant mutant strain H1N1-H275Y. The acids-flavonoids mixture had the strongest inhibitory effects in vitro with EC50 values of 3.8, 4.1, and >20 μg/mL against H1N1, H3N2 and H1N1-H275Y, respectively, showing competitive antiviral activity with oseltamivir and ribavirin. Honeysuckle acids extract also showed the most significant antiviral activity in vivo. Oral administration of the acids extract at a dosage of 600 mg/kg/d effectively alleviated viral pneumonia, maintained body weight and improved the survival rate to 30% of the mice infected with a lethal dose of H1N1. The results of time-of-drug addition experiment and neuraminidase (NA) inhibition assay showed that honeysuckle extracts had a broad-spectrum inhibitory effect against influenza virus NAs. The flavonoid extract showed the strongest inhibitory effect on the NA of influenza virus H7N9 with an IC50 of 24.7 μg/mL. These results suggested that these extracts might exert their antiviral activity by suppressing the release of influenza viruses. Briefly, our findings demonstrate that acids and flavonoids extracts of honeysuckle are the major antiviral active components, and the acids extract has the potential to be developed into an antiviral agent against influenza virus, especially for oseltamivir-resistant viruses.

    • 加载中

      1. Cai WT, Li YT, Chen SR, Wang ML, Zhang AD, Zhou HB, Chen HC, Jin ML (2015) 14-Deoxy-11, 12-dehydroandrographolide exerts anti-influenza A virus activity and inhibits replication of H5N1 virus by restraining nuclear export of viral ribonucleoprotein complexes. Antiviral Res 118: 82–92
          doi: 10.1016/j.antiviral.2015.03.008

      2. Chen H, Deng G, Li Z, Tian G, Li Y, Jiao P, Zhang L, Liu Z, Webster RG, Yu K (2004) The evolution of H5N1 influenza viruses in ducks in southern China. Proc Natl Acad Sci U S A 101: 10452–10457
          doi: 10.1073/pnas.0403212101

      3. Cheng W, Ren J, Huang Q, Long H, Jin H, Zhang L, Liu H, van Ofwegen L, Lin W (2016) Pregnane steroids from a gorgonian coral Subergorgia suberosa with anti-flu virus effects. Steroids 108: 99–104
          doi: 10.1016/j.steroids.2016.02.003

      4. Cinatl J Jr, Michaelis M, Doerr HW (2007) The threat of avian influenza A (H5N1). Part IV: development of vaccines. Med Microbiol Immunol 196: 213–225

      5. Collins PJ, Haire LF, Lin YP, Liu J, Russell RJ, Walker PA, Skehel JJ, Martin SR, Hay AJ, Gamblin SJ (2008) Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature 453: 1258–1261
          doi: 10.1038/nature06956

      6. De Clercq E (2006) Antiviral agents active against influenza A viruses. Nat Rev Drug Discov 5: 1015–1025
          doi: 10.1038/nrd2175

      7. Ding Y, Dou J, Teng Z, Yu J, Wang T, Lu N, Wang H, Zhou C (2014) Antiviral activity of baicalin against influenza A (H1N1/H3N2) virus in cell culture and in mice and its inhibition of neuraminidase. Arch Virol 159: 3269–3278
          doi: 10.1007/s00705-014-2192-2

      8. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL (2013) Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 100: 446–454
          doi: 10.1016/j.antiviral.2013.09.015

      9. Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W, Chen J, Jie Z, Qiu H, Xu K, Xu X, Lu H, Zhu W, Gao Z, Xiang N, Shen Y, He Z, Gu Y, Zhang Z, Yang Y, Zhao X, Zhou L, Li X, Zou S, Zhang Y, Li X, Yang L, Guo J, Dong J, Li Q, Dong L, Zhu Y, Bai T, Wang S, Hao P, Yang W, Zhang Y, Han J, Yu H, Li D, Gao GF, Wu G, Wang Y, Yuan Z, Shu Y (2013) Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 368: 1888–1897
          doi: 10.1056/NEJMoa1304459

      10. Hampson AW (2008) Vaccines for pandemic influenza. The history of our current vaccines, their limitations and the requirements to deal with a pandemic threat. Ann Acad Med Singap 37: 510–517

      11. Hay AJ, Wolstenholme AJ, Skehel JJ, Smith MH (1985) The molecular basis of the specific anti-influenza action of amantadine. EMBO J 4: 3021–3024
          doi: 10.1002/j.1460-2075.1985.tb04038.x

      12. Hayden FG (2006) Antiviral resistance in influenza viruses—Implications for management and pandemic response. N Engl J Med 354: 785–788
          doi: 10.1056/NEJMp068030

      13. Hurt AC (2014) The epidemiology and spread of drug resistant human influenza viruses. Curr Opin Virol 8: 22–29
          doi: 10.1016/j.coviro.2014.04.009

      14. Ison MG (2011) Antivirals and resistance: influenza virus. Curr Opin Virol 1: 563–573
          doi: 10.1016/j.coviro.2011.09.002

      15. Jin J, Chen Y, Wang D, Ma L, Guo M, Zhou C, Dou J (2018) The inhibitory effect of sodium baicalin on oseltamivir-resistant influenza a virus via reduction of neuraminidase activity. Arch Pharm Res 41: 664–676
          doi: 10.1007/s12272-018-1022-6

      16. Jung EJ, Lee KH, Seong BL (2010) Reverse genetic platform for inactivated and live-attenuated influenza vaccine. Exp Mol Med 42: 116–121
          doi: 10.3858/emm.2010.42.2.013

      17. Kim JH, Resende R, Wennekes T, Chen HM, Bance N, Buchini S, Watts AG, Pilling P, Streltsov VA, Petric M, Liggins R, Barrett S, McKimm-Breschkin JL, Niikura M, Withers SG (2013) Mechanism-based covalent neuraminidase inhibitors with broad-spectrum influenza antiviral activity. Science 340: 71–75

      18. Koehn FE, Carter GT (2005) The evolving role of natural products in drug discovery. Nat Rev Drug Discov 4: 206–220
          doi: 10.1038/nrd1657

      19. Leang SK, Deng YM, Shaw R, Caldwell N, Iannello P, Komadina N, Buchy P, Chittaganpitch M, Dwyer DE, Fagan P, Gourinat AC, Hammill F, Horwood PF, Huang QS, Ip PK, Jennings L, Kesson A, Kok T, Kool JL, Levy A, Lin C, Lindsay K, Osman O, Papadakis G, Rahnamal F, Rawlinson W, Redden C, Ridgway J, Sam IC, Svobodova S, Tandoc A, Wickramasinghe G, Williamson J, Wilson N, Yusof MA, Kelso A, Barr IG, Hurt AC (2013) Influenza antiviral resistance in the Asia-Pacific region during 2011. Antiviral Res 97: 206–210
          doi: 10.1016/j.antiviral.2012.12.016

      20. Lee SM, Yen HL (2012) Targeting the host or the virus: current and novel concepts for antiviral approaches against influenza virus infection. Antiviral Res 96: 391–404
          doi: 10.1016/j.antiviral.2012.09.013

      21. Levine MM, Sztein MB (2004) Vaccine development strategies for improving immunization: the role of modern immunology. Nat Immunol 5: 460–464
          doi: 10.1038/ni0504-460

      22. Rohrs S, Kalthoff D, Beer M (2014) A model for early onset of protection against lethal challenge with highly pathogenic H5N1 influenza virus. Vaccine 32: 2631–2636
          doi: 10.1016/j.vaccine.2014.03.019

      23. Sakai T, Nishimura SI, Naito T, Saito M (2017) Influenza A virus hemagglutinin and neuraminidase act as novel motile machinery. Sci Rep 7: 45043
          doi: 10.1038/srep45043

      24. Tarbet EB, Hamilton S, Vollmer AH, Luttick A, Ng WC, Pryor M, Hurst BL, Crawford S, Smee DF, Tucker SP (2014) A zanamivir dimer with prophylactic and enhanced therapeutic activity against influenza viruses. J Antimicrob Chemother 69: 2164–2174
          doi: 10.1093/jac/dku127

      25. Taubenberger JK, Kash JC (2010) Influenza virus evolution, host adaptation, and pandemic formation. Cell Host Microb 7: 440–451
          doi: 10.1016/j.chom.2010.05.009

      26. Thorlund K, Awad T, Boivin G, Thabane L (2011) Systematic review of influenza resistance to the neuraminidase inhibitors. BMC Infect Dis 11: 134
          doi: 10.1186/1471-2334-11-134

      27. Tian L, Wang ZY, Wu H, Wang S, Wang Y, Wang YY, Xu JW, Wang LY, Qi FC, Fang ML, Yu DH, Fang XX (2011) Evaluation of the anti-neuraminidase activity of the traditional Chinese medicines and determination of the anti-influenza A virus effects of the neuraminidase inhibitory TCMs in vitro and in vivo. J Ethnopharmacol 137: 534–542
          doi: 10.1016/j.jep.2011.06.002

      28. Yu J, Wang D, Jin J, Xu J, Li M, Wang H, Dou J, Zhou C (2016) Antiviral activity of SA-2 against influenza A virus in vitro/vivo and its inhibition of RNA polymerase. Antiviral Res 127: 68–78
          doi: 10.1016/j.antiviral.2016.01.011

      29. Zhang J, Liu T, Tong X, Li G, Yan J, Ye X (2012) Identification of novel virus inhibitors by influenza A virus specific reporter cell based screening. Antiviral Res 93: 48–54
          doi: 10.1016/j.antiviral.2011.10.014

      30. Zhang Q, Shi J, Deng G, Guo J, Zeng X, He X, Kong H, Gu C, Li X, Liu J, Wang G, Chen Y, Liu L, Liang L, Li Y, Fan J, Wang J, Li W, Guan L, Li Q, Yang H, Chen P, Jiang L, Guan Y, Xin X, Jiang Y, Tian G, Wang X, Qiao C, Li C, Bu Z, Chen H (2013) H7N9 influenza viruses are transmissible in ferrets by respiratory droplet. Science 341: 410–414
          doi: 10.1126/science.1240532

      31. Zhou Z, Li XH, Liu JX, Dong L, Chen Q, Liu JL, Kong HH, Zhang QY, Qi X, Hou DX, Zhang L, Zhang GQ, Liu YC, Zhang YJ, Li J, Wang J, Chen X, Wang H, Zhang JF, Chen HL, Zen K, Zhang CY (2015) Honeysuckle-encoded atypical microRNA2911 directly targets influenza A viruses. Cell Res 25: 39–49
          doi: 10.1038/cr.2014.130

    • 加载中

    Figures(4) / Tables(2)

    PDF

    Article Metrics

    Article views(21744) PDF downloads(50) Cited by()

    Related
    Proportional views

      Inhibitory Activity of Honeysuckle Extracts against Influenza A Virus In Vitro and In Vivo

        Corresponding author: Changlin Zhou, cl_zhou@cpu.edu.cn
        Corresponding author: Min Guo, 1020152471@cpu.edu.cn
      • 1. State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, China
      • 2. Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, Nanjing 210009, China
      • 3. Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China
      • Received Date: 19 July 2019
      • Accepted Date: 11 September 2020
      • Published Date: 12 October 2020

      Abstract: 

      Honeysuckle has been used in the treatment of influenza virus infection for thousands of years in China. However, its main active components and the functional mechanisms remain to be elucidated. Here, four honeysuckle extracts, including acids extract, flavonoids extract, total extract and acids-flavonoids mixture, were prepared to clarify the main active antiviral components. The cytopathic effect reduction assay showed that all the four extracts inhibited the replication of influenza viruses H1N1, H3N2 and the oseltamivir-resistant mutant strain H1N1-H275Y. The acids-flavonoids mixture had the strongest inhibitory effects in vitro with EC50 values of 3.8, 4.1, and >20 μg/mL against H1N1, H3N2 and H1N1-H275Y, respectively, showing competitive antiviral activity with oseltamivir and ribavirin. Honeysuckle acids extract also showed the most significant antiviral activity in vivo. Oral administration of the acids extract at a dosage of 600 mg/kg/d effectively alleviated viral pneumonia, maintained body weight and improved the survival rate to 30% of the mice infected with a lethal dose of H1N1. The results of time-of-drug addition experiment and neuraminidase (NA) inhibition assay showed that honeysuckle extracts had a broad-spectrum inhibitory effect against influenza virus NAs. The flavonoid extract showed the strongest inhibitory effect on the NA of influenza virus H7N9 with an IC50 of 24.7 μg/mL. These results suggested that these extracts might exert their antiviral activity by suppressing the release of influenza viruses. Briefly, our findings demonstrate that acids and flavonoids extracts of honeysuckle are the major antiviral active components, and the acids extract has the potential to be developed into an antiviral agent against influenza virus, especially for oseltamivir-resistant viruses.

        HTML